Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Authors:
- Rishi SuranaRSRishi Surana
- Micaela MorgadoMMMicaela Morgado
- Ashwin SomasundaramASAshwin Somasundaram
- Bruno BockornyBBBruno Bockorny
- Emma C. ColemanECEmma C. Coleman
- Junning WangJWJunning Wang
- Hannah L. WilliamsHWHannah L. Williams
- Hui ZhengHZHui Zheng
- Lauren K. BraisLBLauren K. Brais
- Neetu SaxenaNSNeetu Saxena
- 1 September 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500332
Abstract
PURPOSE: Oncogenic mutations in Kirsten rat sarcoma virus are present in over 90% of pancreatic ductal adenocarcinomas (PDACs). Preclinical data suggest that PDAC cells treated with inhibitors of the mitogen-activated protein kinase pathway demonstrate elevated autophagic flux. In this study, we evaluate the clinical efficacy of combining LY3214996 (extracellular regulated kinase inhibitor) with hydroxychloroquine (HCQ; autophagy inhibitor) in patients with metastatic PDAC. METHODS: Eligible patients had metastatic PDAC and at least one, but no more than two prior lines of systemic therapy. A safety lead-in evaluating the combination was conducted and the maximum tolerated dose level of LY3214996 was identified. Patients were then randomly assigned in a 1:1 fashion to receive either LY3214996 200 mg orally (PO) once daily + HCQ 600 mg PO twice a day (arm 1) or LY3214996 400 mg PO once daily (arm 2). The primary end point for this study was disease control rate (DCR). Secondary end points included overall survival (OS) and progression-free survival (PFS). RESULTS: Thirty-nine patients enrolled (20 in arm 1, 19 in arm 2). The DCR rates were 5% in arm 1 and 5.3% in arm 2. The median OS was 2.4 months in arm 1 (95% CI, 1.3 to 5.8) and 4.6 months in arm 2 (95% CI, 3.1 to 5.7). The median PFS was 1.3 months in arm 1 (95% CI, 0.8 to 1.8) and 1.9 months in arm 2 (95% CI, 1.644 to 2.4). The most frequently observed toxicities in both arms included nausea, diarrhea, elevated creatine phosphokinase, anorexia, and cytopenias. Exploratory analysis using patient-derived PDAC organoids did not show evidence of synergistic antiproliferative activity of LY3214996 in combination with chloroquine. CONCLUSION: LY3214996 alone or in combination with HCQ did not result in clinical activity in patients with metastatic PDAC.Keywords
This publication has 36 references indexed in Scilit:
- 514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)European Journal of Cancer, 2024
- Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerCell, 2021
- Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancerNature Cancer, 2021
- Autophagy as a therapeutic target in pancreatic cancerBritish Journal of Cancer, 2020
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerNature Medicine, 2019
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersNature Medicine, 2019
- MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalProceedings of the National Academy of Sciences, 2019
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerInternational Journal of Cancer, 2018
- A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorBritish Journal of Cancer, 2017
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapyInvestigational New Drugs, 2011